Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Texidrofolico is a pharmaceutical product marketed in some Spanish-speaking countries, most notably Mexico. It is not recognized as an international nonproprietary name (INN) or by major regulatory agencies such as the FDA or EMA. The name "texidrofolico" appears to be a brand or trade name rather than a generic drug name. Based on available information and naming conventions, "texidrofolico" likely refers to folic acid (vitamin B9) or a related folate compound, possibly in combination with other vitamins or minerals for use as a dietary supplement, particularly in pregnancy for the prevention of neural tube defects and treatment of folate deficiency anemia. However, there is no evidence that it contains any antiretroviral agents such as tenofovir, nor does it appear in major pharmaceutical databases under this spelling.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on texidrofolico.